JAAD case reports|2025|Talasila S et al.|3 citations
Case Report
PMID: 39845462
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Semaglutide is a medication for weight loss in obese patients. Recently, many plastic surgeons have recommended semaglutide following bariatric surgery to increase weight loss. However, postoperative complications such as wound dehiscence…
SUMMARY: Semaglutide, a GLP-1 receptor agonist (RA), is approved for the treatment of type 2 diabetes and obesity. However, its increasing off-label use, particularly for cosmetic weight loss, raises concerns considering its potential adverse effects…
Recent cardiovascular outcome trials (CVOTs) have reshaped the therapeutic landscape of type 2 diabetes mellitus (T2DM), revealing that certain glucose-lowering agents, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), offer substantial…
Obesity, type 2 diabetes, and therapeutic weight loss are all associated with impaired bone quantity and microarchitecture. Glucagon-like peptide receptor analogs (GLP1RAs) have direct beneficial effects on bone microarchitecture, in preclinical sett…
AIM: This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RAs), on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs). METHODS AND RESULTS: Twenty-six RCTs involving 48,…
BACKGROUND: Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg (Wegovy) has benefited from an early-access program from July 2022 to September 2023. OBJECTIVE: This study aimed t…
BackgroundAlmost half of the dementia cases are preventable. Semaglutide treats several medical conditions that are risk factors for dementia.ObjectiveWe aim to investigate if semaglutide is associated with a decreased risk of dementia.MethodsWe cond…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely accepted for managing Type 2 diabetes mellitus. However, numerous drug-related problems (DRPs) have recently been reported about GLP-1 RAs. OBJECTIVES: The present descripti…
PURPOSE: To investigate whether semaglutide increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in the general population. DESIGN: This retrospective cohort study used a deidentified global electronic medical records databas…
AIMS: The study aims to examine the outcome of replacement of prandial insulin with once-weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections (MDI). MATERIALS AND METHODS: This sing…
Neuronal injury is a common complication in patients with diabetes. These injuries include a wide range of neurobehavioral complications that significantly reduce the neuronal network efficiency and quality of life in affected individuals. Currently,…
AIMS: To evaluate the association between tirzepatide and the risk of developing erectile dysfunction (ED) in men with type 2 diabetes (T2D), compared with sitagliptin, injectable semaglutide, and dulaglutide. METHODS: This retrospective cohort study…
OBJECTIVE: This study was designed to evaluate the effects of Semaglutide and adenosine on kidney protein expression in obese mice induced by a high-fat diet (HFD), to identify signaling pathways involved in the obesity-related glomerulonephropathy (…
AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a cornerstone in type 2 diabetes management. In this study we evaluated heterogeneity in body weight and glycaemic responses to the initiation of liraglutide, semaglutide or d…